Vaccinex Presented data on VX15/2503 at CRI Cancer Immunotherapy 2013 Conference

ROCHESTER, NY – Vaccinex Inc., a clinical stage biotechnology company focused on the development of novel immune-based therapeutics has presented information regarding VX15/2503, the company’s leading therapeutic antibody program. A poster was available for viewing at the 21st annual International Cancer Immunotherapy Symposium entitled Dynamics of Host-Tumor Interaction September 30th – October 2nd, 2013 in New York, NY. VX15/2503 antibody targets SEMA4D. Blockade of SEMA4D reduces tumor growth through effects on tumor microenvironment, angiogenesis and vascular permeability, and, possibly, direct effects on tumor. Antibody neutralization of SEMA4D may, therefore, represent a new therapeutic strategy for cancer treatment. The humanized antibody, VX15/2503, has successfully completed IND-enabling toxicology testing and the dose escalation phase of a Phase I trial in adult patients with advanced solid tumors.

A link to the pertinent presentation is provided below.
(CRI) – Reduction of tumor growth by an antibody to SEMA4D/MAb67

About Vaccinex, Inc.
Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases.